|
|
|
| Effects of quality of life in patients with intermediate and advanced lung cancer undergoing different treatment regimens |
| WANG Yue1, HUANG Xiaotong2, ZHAO Fei1, Ding Lili1, WU Bingyi1
|
1. School of Management, Shandong Second Medical University, Weifang, Shandong 261053, China;
2. School of Nursing, Shandong Second Medical University, Weifang, Shandong 261053, China |
|
|
|
|
Abstract Objective To examine the impacts of chemotherapy/radiotherapy, targeted therapy, and combined treatment on the quality of life in patients with intermediate and advanced lung cancer. Methods The patients with intermediate and advanced lung cancer undergoing chemotherapy/radiotherapy, targeted therapy, and combined treatment for the first time were recruited from a tertiary hospital in Weifang City, Shandong Province, using a quota sampling method in September 2023. Basic information was collected using a general information questionnaire, and the quality of life was assessed using the Chinese version of Functional Assessment of Cancer Therapy-General. The investigation started on the 7th day of treatment, and the follow-ups were conducted at 3 and 6 months. The quality of life in patients with different treatment regimens and at different treatment time were compared using repeated measure analysis of variance. Results There were 26 chemotherapy/radiotherapy patients, 32 targeted therapy patients, and 95 combination therapy patients. There were no significant differences in age, gender, place of residence, education level, self-rated economic status, medical insurance, pathological type and disease stage among the three treatment regimens (all P>0.05). The repeated measure analysis of variance showed an interaction effect between time and group among patients receiving the three treatment regimens (P<0.05). The quality of life scores of patients receiving combination therapy decreased with extended treatment time (all P<0.05). The quality of life scores of patients receiving targeted therapy at 3 and 6 months were lower than those treated for 7 days (both P<0.05). No significant differences were observed in quality of life scores among chemotherapy/radiotherapy patients with different treatment durations (all P>0.05). At 3 and 6 months, patients receiving combination therapy had lower quality of life scores compared to those receiving chemotherapy/radiotherapy or targeted therapy (all P<0.05). Conclusion The decline in quality of life for patients with intermediate and advanced lung cancer undergoing chemotherapy/radiotherapy and targeted therapy is less than that for patients receiving combined therapy.
|
|
Received: 05 September 2024
Revised: 17 February 2025
Published: 17 March 2025
|
|
|
|
|
|
[1] HAN B F,ZHENG R S,ZENG H M,et al.Cancer incidence and mortality in China,2022[J].J Natl Cancer Cent,2024,4(1):47-53.
[2] KARANIKAS M,ESEMPIDIS A,CHASAN Z T,et al.Pancreatic cancer from molecular pathways to treatment opinion[J].J Cancer,2016,7(10):1328-1339.
[3] CHOU H L,CHAO T Y,CHEN T C,et al.The relationship between inflammatory biomarkers and symptom distress in lung cancer patients undergoing chemotherapy[J].Cancer Nurs,2017,40(2):1-8.
[4] 高月霞,徐程,刘国恩,等.社会支持对老年人健康相关生命质量影响研究——基于南通的实证[J].人口与发展,2013,19(4):73-81.
GAO Y X,XU C,LIU G E,et al.Social support and health related quality of life of the elderly:evidence from Nantong[J].Popul Dev,2013,19(4):73-81.(in Chinese)
[5] YUAN T,ZHOU Y,WANG T,et al.Impact research of pain nursing combined with hospice care on quality of life for patients with advanced lung cancer[J].Medicine(Baltimore),2024,103(22):1-8.
[6] 中华医学会肿瘤学分会.中华医学会肺癌临床诊疗指南(2024版)[J].中华肿瘤杂志,2024,46(9):805-843.
Oncology Society of Chinese Medical Association.Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer(2024 edition)[J].Chin J Oncol,2024,46(9):805-843.(in Chinese)
[7] TRAVIS W D,BRAMBILLA E,NICHOLSON A G,et al.The 2015 World Health Organization classification of lung tumors:impact of genetic,clinical and radiologic advances since the 2004 classification[J].J Thorac Oncol,2015,10(9):1243-1260.
[8] 万崇华,孟琼,汤学良,等.癌症患者生命质量测定量表FACT-G中文版评介[J].实用肿瘤杂志,2006,21(1):77-80.
WAN C H,MENG Q,TANG X L,et al.A review of the Chinese version of the Functional Assessment of Cancer Therapy-General(FACT-G)[J].J Prac Oncol,2006,21(1):77-80.(in Chinese)
[9] 杨鹏. 靶向药物的研究进展与开发前沿[J].药学进展,2020,44(9):641-643.
YANG P.Research progress and development frontier of targeting drugs[J].Prog Pharm Sci,2020,44(9):641-643.(in Chinese)
[10] 伍志新. 晚期肺癌患者靶向药物治疗的应用及对生命质量影响评估[J].中国农村卫生,2021,13(15):30-31.
WU Z X.Application of targeted drug therapy in patients with advanced lung cancer and assessment of its impact on quality of life[J].China Rural Health,2021,13(15):30-31.(in Chinese)
[11] 刘卓环,罗美华,邹爱梅,等.靶向药物对EGFR基因突变的晚期肺癌患者生命质量的影响分析[J].中国实用医药,2020,15(33):99-101.
LIU Z H,LUO M H,ZOU A M,et al.Effect of targeted drugs on the quality of life of advanced lung cancer patients with EGFR gene mutation[J].China Prac Med,2020,15(33):99-101.(in Chinese)
[12] 杨海玉,郭娇,孙元明,等.放射性脑损伤机制与防治方法研究进展[J].辐射防护,2020,40(4):346-352.
YANG H Y,GUO J,SUN Y M,et al.Review on the mechanism,prevention and treatments of radiation brain injury[J].Radiat Prot,2020,40(4):346-352.(in Chinese)
[13] 白美蓉,张爱华.肺癌患者心理状态、支持性照护需求与生存质量的关系研究[J].当代护士(下旬刊),2023,30(7):95-101.
BAI M R,ZHANG A H.A study of the relationship between psychological status,supportive care needs and quality of survival in lung cancer patients[J].Mod Nurse,2023,30(7):95-101.(in Chinese) |
|
|
|
